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Overexpression of TIMP-1 in Embryonic Stem Cells Attenuates Adverse 
Cardiac Remodeling Following Myocardial Infarction
Carley Glass and Dinender K. Singla
Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, FL, USA
Transplanted embryonic stem (ES) cells, following myocardial infarction (MI), contribute to limited cardiac 
repair and regeneration with improved function. Therefore, novel strategies are still needed to understand 
the effects of genetically modified transplanted stem cells on cardiac remodeling. The present study evalu-
ates whether transplanted mouse ES cells overexpressing TIMP-1, an antiapoptotic and antifibrotic protein, 
can enhance cardiac myocyte differentiation, inhibit native cardiac myocyte apoptosis, reduce fibrosis, and 
improve cardiac function in the infarcted myocardium. MI was produced in C57BL/6 mice by coronary artery 
ligation. TIMP-1-ES cells, ES cells, or culture medium (control) were transplanted into the peri-infarct region 
of the heart. Immunofluorescence, TUNEL staining, caspase-3 activity, ELISAs, histology, and echocardiog-
raphy were used to identify newly differentiated cardiac myocytes and assess apoptosis, fibrosis, and heart 
function. Two weeks post-MI, significantly ( p < 0.05) enhanced engraftment and cardiac myocyte differentia-
tion was observed in TIMP-1-ES cell-transplanted hearts compared with hearts transplanted with ES cells and 
control. Hearts transplanted with TIMP-1-ES cells demonstrated a reduction in apoptosis as well as an increase 
( p < 0.05) in p-Akt activity compared with ES cells or culture media controls. Infarct size and interstitial and 
vascular fibrosis were significantly ( p < 0.05) decreased in the TIMP-1-ES cell group compared to controls. 
Furthermore, MMP-9, a key profibrotic protein, was significantly ( p < 0.01) reduced following TIMP-1-ES cell 
transplantation. Echocardiography data showed fractional shortening and ejection fraction were significantly 
( p < 0.05) improved in the TIMP-1-ES cell group compared with respective controls. Our data suggest that 
transplanted ES cells overexpressing TIMP-1 attenuate adverse myocardial remodeling and improve cardiac 
function compared with ES cells that may have therapeutic potential in regenerative medicine.
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cell death via apoptosis and necrosis, fibrosis, and hyper-
trophy leading to end stage heart failure (2,15,19,25,34). 
In response to myocardial cell death post-MI, increased 
expression of extracellular matrix (ECM) proteins, spe-
cifically collagen types I and III, occurs evoking fibrosis 
formation (23,40). Fibrosis within the injured myocardium 
causes stiffening of the heart and overall systolic and dia-
stolic dysfunction. Matrix metalloproteinases (MMPs) are 
a family of endopeptidases, which play a fundamental role 
in the degradation and aberrant production of ECM pro-
teins leading to alterations in ventricular architect post-MI. 
Tissue inhibitors of metalloproteinases (TIMPs) are innate 
protease inhibitors of MMPs. TIMP-1, the most exten-
sively characterized TIMP, is not only a well-documented 
anti fibrotic protein (6,7,12) but also has recently been 
shown to exhibit antiapoptotic characteristics in noncar-
diac cell types such as breast epithelial cells (22,35,44). 
Moreover, we were the first to report that TIMP-1 is a cyto-
protective released factor from ES cells, which prevents 
INTRODUCTION
Cell transplantation strategies using renewable sources 
of cardiac myocytes to repair damaged myocardium, 
replace lost cardiac cells, and prevent remodeling fol-
lowing myocardial infarction (MI) has gained significant 
attention. We, as well as others, have shown that trans-
planted embryonic stem (ES) cells post-MI have the 
potential to engraft, differentiate into cardiac-specific 
cell types, limit adverse myocardial remodeling, and 
improve heart function (3,14,33,34). However, inhibition 
of adverse cardiac remodeling following cell transplanta-
tion is minimal relative to normal heart architecture and 
overall cardiac function. Therefore, novel approaches are 
needed to augment the efficacy by which transplanted ES 
cells enhance cardiac repair in order to optimize cardiac 
regain of function following cell transplantation therapy.
Following myocardial infarction, ventricular architec-
tural remodeling consequent to MI is characterized by var-
ious physiological and cellular changes including cardiac 
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H2O2-induced apoptosis in vitro in cardiomyoblasts (H9c2 
cells) (35). However, whether TIMP-1, when overex-
pressed in transplanted ES cells, can impact adverse car-
diac remodeling post-MI by blunting host myocardium 
apoptosis and fibrosis has yet to be delineated.
In the present study, we hypothesize that ES cells over-
expressing TIMP-1 (TIMP-1-ES cells), following trans-
plantation into the infarcted myocardium, will attenuate 
apoptosis and fibrosis along with improving cardiac func-
tion. To accomplish this hypothesis, we generated ES cells 
overexpressing TIMP-1 (TIMP-1-ES cells), transplanted 
them into the infarcted myocardium, and evaluated their 
impact on engraftment, cardiac myocyte differentiation, 
apoptosis, fibrosis, and associated cardiac function. Our 
data show that TIMP-1-ES cells engraft and differentiate 
into cardiac mycoytes in the infarcted myocardium. We 
also suggest transplanted TIMP-1-ES cells post-MI signif-
icantly inhibit cardiac myocyte apoptosis compared with 
ES cells and the antiapoptotic effect of TIMP-1 is, in part, 
mediated through the Akt pathway. Furthermore, we dem-
onstrate that transplanted TIMP-1-ES cells inhibit both 
interstitial and vascular fibrosis in the infarcted myocar-
dium. Finally, we show that transplantation of TIMP-1-ES 
cells post-MI significantly enhances cardiac function. 
MATERIALS AND METHODS
ES Cell Culture
CGR8 ES cells with or without TIMP-1 were cultured 
and maintained on 0.1% gelatin-coated tissue culture plates 
in Dulbecco’s minimum essential medium (DMEM) growth 
media supplemented with leukemia inhibitory factor (LIF), 
sodium pyruvate, glutamine, penicillin/streptomycin, nones-
sential amino acids, b- mercaptoethanol, and 15% ES quali-
fied fetal bovine serum as we previously reported (38).
TIMP-1-ES Cell Generation
The mammalian expression vector (pTurboFP635-C) 
encoding red fluorescent protein (RFP) was purchased 
from Evrogen (Moscow, Russia). The cDNAs coding 
mouse TIMP-1 gene were generated by PCR cloning 
using high-fidelity DNA polymerase and PCR prim-
ers (forward, 5¢-AGAGCAGATACCATGATG-3¢ and 
reverse, 5¢-GAAGGCTTCAGGTCATCG-3¢). The PCR 
product was cloned to the Bgl II and BamH l site of the 
pTurboFP635 C-terminus as a single open reading frame 
to code for a TIMP-1/RFP fusion protein. The expression 
vector contained a neomycin resistance gene for selection 
of stable transfectants in CGR8 ES cell lines. The sequence 
of mouse TIMP-1 gene was confirmed by restriction 
enzyme digestion and DNA sequencing analysis. 
CGR8 mouse ES cells were transfected with the 
TIMP-1 expression vector using Lipofectamine 2000 
(In vitro gen). Selection media containing 100 mg/ml of 
the selective antibiotic G418 (Invitrogen) was added 48 h 
posttransfection. Selection medium was changed every 
48 h, and cells were maintained for 2–3 weeks. Thereafter, 
G418-resistant ES cell colonies (labeled TIMP-1-ES 
cells) were selected, expanded, and maintained in ES cell 
culture medium. TIMP-1-ES cell clones were confirmed 
with elevated TIMP-1 protein expression as compared to 
parental CGR8 ES cells through Western blot analysis 
using a primary antibody against TIMP-1 (sc-5538, Santa 
Cruz) followed by incubation with goat anti-rabbit IgG 
secondary antibody (sc-2004, Santa Cruz). 
TIMP-1 ELISA
Levels of secreted TIMP-1 were measured using a 
Ray Bio® Mouse TIMP-1 ELISA kit (ELM-TIMP1-001) 
as per the manufacturer’s instructions. In brief, 1 week 
 posttransfection and selection, medium was collected 
from tissue culture dishes containing growing ES and 
TIMP-1-ES cells. Samples were added for 2.5 h to the 
precoated wells, washed and incubated with biotiny lated 
antibody for an additional hour. Following wash ings, 
horse radish peroxidase (HRP)-conjugated streptavidin 
solution was added for 45 min followed by incubation 
with the substrate solution for 30 min. Immediately there-
after, a stop solution was added and the color intensity 
was measured at 450 nm. The values obtained from the 
ELISA were corrected for the total protein concentration 
of each sample as estimated by the Bradford assay. 
MI and Cell Transplantation
All mice were maintained and used as approved by the 
institutional animal review board. C57BL/6 mice (8–10 
weeks old) were divided into four study groups (n = 8 per 
group): Sham, MI + cell culture media (MI + CC), MI + ES 
cells, and MI + TIMP-1-ES cells. In brief, mice were 
anesthetized, endotracheally intubated, and ventilated 
using a rodent MiniVent (Harvard Apparatus). Anesthesia 
was maintained using 2.5% isoflurane throughout the 
procedure. Left thoracotomy was performed, and the 
descending left coronary artery was permanently ligated 
as we reported previously (18). Following ligation, two 
intramyocardial injections of 10 ml of medium containing 
2.5 ´  104 TIMP-1-ES cells or ES cells were delivered into 
the peri-infarct region. The chest was then closed, lungs 
expanded, and mice were weaned from the ventilator and 
extubated. Sham group animals received all identical sur-
gical procedures with the exception of no coronary artery 
ligation. Mice received postoperative care, including 
analgesia (buprenorphine, 0.5 mg/kg), for 2 days or until 
normal behavior resumed. Day 1 (D1) and D14 following 
surgery, mice were sacrificed by pentobarbital (80 mg/kg) 
followed by cervical dislocation. Hearts were removed, 
transversely cut, and fixed in 4% paraformaldehyde for 
further evaluation.
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Histopathology 
Heart tissue was embedded and sectioned as previ-
ously described (34). In brief, heart tissue was embed-
ded in paraffin blocks, cut in serial sections (5 mm), and 
placed onto Colorfrost Plus microscope slides (Fisher 
Scientific). Heart sections were deparaffinized using 
room temperature xylene followed by sequential incu-
bation in 100%, 95%, and 70% ethanol for 3 min and 
washed with distilled water. Heart sections were then 
stained with Mason's trichrome. Left ventricular (LV) 
infarct size was quantified by measuring the total LV 
infarct area/LV area ´  100%. To quantify interstitial fibro-
sis, infarct, peri-infarct, and noninfarct regions of the 
heart were examined, and fibrosis was quantified by mea-
suring the total blue area/total heart area ´  100%. Vascular 
fibrosis was quantified by measuring vascular fibrosis/
vessel area ´  100% in one to two sections from five to 
eight hearts per group. All fibrosis measurements were 
made using NIH ImageJ software.
Immunohistochemistry
To quantify engrafted transplanted cells at D1 and D14 
following MI, heart sections were deparaffinized as afore-
mentioned and immunohistochemically stained using 
primary antibodies against RFP (AB232, Evrogen) and 
octamer-binding transcription protein 3/4 (Oct 3/4; sc- 
5279, Santa Cruz). Heart sections were then incubated 
with Alexa 488- or Alexa 568-conjugated secondary anti-
bodies (Invitrogen), respectively. Sections were washed, 
air dried, and mounted with Antifade Vectashield mount-
ing medium. Colocalization of RFP and Oct 3/4-positive 
cells were counted as engrafted transplanted cells in one to 
two heart sections from n = 6–8 animals/group. To quan-
tify the amount of differentiated cardiac myocytes from 
transplanted cells at D14, hearts were immunohistochemi-
cally stained with primary antibodies against sarcomeric 
a-actin (A2172, Sigma) and RFP (AB232, Evrogen) fol-
lowed by incubation with appropriate secondary antibod-
ies. Cells positive for both sarcomeric a-actin and RFP 
were counted as newly differentiated cardiac myocytes 
derived from transplanted stem cells. Visualization of 
engrafted and differentiated cells was performed using 
Olympus fluorescent and Leica TSC SP2 laser scanning 
confocal microscopes.
TUNEL and Cardiac a-Actin Staining 
Terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) staining was performed as previously 
described (36). In brief, heart sections were deparaf-
finized and permeabilized with proteinase K (25 mg/ml 
in 100 mM Tris–HCl). The TUNEL assay kit (TMR red; 
Roche Applied Biosystems) was used as per the manufac-
turer’s instructions to detect host myocardium apoptotic 
nuclei. Apoptotic cells were colabeled with cardiac a-actin 
(A2172, Sigma) to detect apoptosis within cardiac myo-
cytes. Heart sections were then mounted with Antifade 
Vectashield mounting medium containing 4¢,6-diamidino-
2-phenylindole (DAPI; Vector Laboratories) for nuclear 
staining and observed under Olympus and confocal 
microscopes: percentage of total apoptotic nuclei = (total 
number of red stained apoptotic nuclei)/(total number of 
blue stained nuclei with DAPI) ´  100. Additionally, the 
percentage of apoptotic nuclei in cardiac myocytes was 
also determined by (total number of red stained apoptotic 
nuclei colocalized with sarcomeric a-actin)/(total number 
of blue stained nuclei with DAPI) ´  100. Total apoptotic 
nuclei and apoptotic cardiac myocyte nuclei were quanti-
tated in the infarct and peri-infarct regions of the heart in 
one to two sections from five to eight hearts from each 
group. These cell counts were performed as previously 
reported by us and others (9,13,37).
Caspase-3 Activity Assay
Caspase-3 activity was quantitated using a caspase-3 
colorimetric activity assay kit (K106-200, BioVision). 
Hearts were homogenized in RIPA buffer containing pro-
tease inhibitor cocktail (Sigma), phenylmethylsulfonyl 
fluoride (PMSF) (1 mM), sodium orthovandate (2 mM), 
and sodium fluoride (5 mM), collected, and centrifuged 
at 11,766 rpms for 5 min. The supernatant was removed, 
and protein concentration estimation was performed 
using a Bio Rad assay. Manufacturer’s instructions were 
followed to complete the activity assay. Developed blue 
color was measured in a microtiter plate reader (Bio Rad) 
at 405 nm. Caspase-3 activity graph was plotted as arbi-
trary units (A.U.).
Phosphorylated Akt Activity Assay
Phosphorylated Akt (p-Akt) was quantitated using a 
phospho-Akt1 (PAN) ELISA kit (X1844k, Exalpha Bio-
logical) as previously described and detailed in the instruc-
tion manual provided with the kit (37). In brief, hearts 
were homogenized, and proteins were estimated by the 
Bradford method. Samples (25 ml) and sample diluents 
(75 ml) were added to the wells labeled with captured 
antibodies provided in the kit for 2 h. Following wash-
ing, samples were incubated with detector antibody for 
2 h, HRP conjugate for 30 min, and substrate for 30 min 
with washings in between each step. A stop solution was 
added and the developed yellow color was measured in a 
microtiter plate reader (Bio Rad) at 450 nm. Phospho-Akt 
graph was plotted as detailed in the kit.
MMP-9 Immunoassay
MMP-9 concentration was determined by an enzyme-
linked immunoassay (MMPT90, R&D Systems). In brief, 
hearts from n = 8 animals/group were homogenized, and 
protein concentrations were estimated as aforemention ed. 
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Samples were loaded into monoclonal MMP-9-immobilized 
antibody-coated wells provided in the kit for 2 h. Fol low-
ing washings, a conjugate (polyclonal antibody for mouse 
MMP-9) was added for an additional 2 h. Again the wells 
were washed, and a substrate solution was added to each 
well for 30 min followed by the addition of a stop solution. 
A color reaction developed proportional to the amount of 
bound MMP-9 and was measured in a microtiter plate 
reader (Bio Rad) at 450 nm. MMP-9 graph was plotted as 
arbitrary units (A.U.). 
Echocardiography
Cardiac function for all mice groups was assessed 
non invasively by transthoracic echocardiography at D14. 
Mice were anesthetized with 2% isoflurane, placed and 
maintained on a temperature-controlled heating pad, and 
the chest was shaved. Echocardiography was performed 
using a Phillips Sonos 5500 Ultrasound system with a 
15-6L hockey stick transducer. Left ventricular internal 
dimension-diastole (LVIDd), left ventricular internal 
dimension-systole (LVIDs), fractional shortening (LVIDd- 
LVIDs/LVIDd ´  100), and eject ion fraction [left ventricu -
lar volume at end diastole (EDV) – left ventricular vol-
ume at end systole (ESV)/EDV] were calculated using 
the Teichholz formula (41) at the midpapillary muscle 
level in short-axis view.
Statistical Analysis
All values presented as a mean ± SEM. Statistical anal-
ysis was performed using the students’ t-test, one-way 
analysis of variance (ANOVA), and the Bonferroni test. 
Statistical significance was assigned when p < 0.05. 
RESULTS
To elucidate the impact of TIMP-1 in transplanted ES 
cells post-MI on cardiac remodeling and function, we 
overexpressed TIMP-1 (Fig. 1A–C) in CGR8 ES cells. 
Fol lowing selection with G418, TIMP-1-ES cells were 
maintained in cell culture for 10–12 weeks. To determine 
stable transfection, Western blot analysis was performed, 
and our data shows a ~49 kDa fusion protein band rep-
resentative of TIMP-1/RFP expression in TIMP-1-ES 
cells compared to parental ES cells ( p < 0.001) (Fig. 1D). 
Additionally, to understand whether TIMP-1 is secreted 
in the conditioned media (CM) obtained from ES and 
TIMP-1-ES cells, a TIMP-1 ELISA was performed on 
ES-CM and TIMP-1-ES-CM. Our quantitative data show 
a dramatic change in secreted TIMP-1 in TIMP-1-ES-CM 
relative to ES-CM ( p < 0.05) (Fig. 1E).
Enhanced Engraftment and Cardiac Myocyte 
Differentiation in TIMP-1-ES Cell Transplanted Hearts
To assess the impact of TIMP-1 overexpression 
in transplanted ES cells on engraftment into the host 
myocardium, heart sections were double immunolabeled 
with antibodies against RFP to detect donor transplanted 
cells and Oct 3/4, a marker indicative of pluripotent 
stem cells (Fig. 2). Figure 2A and E shows Oct 3/4-
 positive cells in red, Figure 2F shows RFP-positive cells 
in green whereas no such cells are present in the MI + CC 
group (Fig. 2B), DAPI is shown in blue in Figure 2C 
and G, and merged images are depicted in Figure 2D 
and H. The boxed area in Figure 2H is enlarged to show 
colocalization of Oct 3/4, RFP, and DAPI in the TIMP-
1-ES cell group. At D1, no significant difference was 
observed in the amount of engrafted transplanted ES or 
TIMP-1-ES cells (Fig. 2I). However, at D14 a dramatic 
difference in the amount of engrafted TIMP-1-ES cells 
was quantified relative to the amount of engrafted ES 
cells ( p < 0.05) (Fig. 2J). 
To quantify cardiac myocyte differentiation from 
transplanted ES and TIMP-1-ES cells, heart sections 
were double immunolabeled with antibodies against RFP 
and the cardiac myocyte marker, sarcomeric a-actin. 
Colocalization of RFP-positive cells with a-actin positive 
cells were counted as newly differentiated cardiac myo-
cytes from transplanted stem cells (Fig. 3). Figure 3A, 
E, I, and M shows a-actin-positive cardiac myocytes 
(red), Figure 3J and N shows transplanted donor cells 
(green) whereas no such cells were present in the sham 
or MI + CC group (Fig. 3B, F), Figure 3C, G, K, and 
O shows total nuclei stained with DAPI (blue), and 
Fig ure 3D, H, L, and P shows merged images of triple- 
labeled sections depicting differentiated cardiac myocytes 
from donor transplanted cells. Upon quantification, we 
reveal TIMP-1-ES cell-transplanted hearts contain sig-
nificantly more donor-differentiated cardiac myocytes 
compared to ES cell-transplanted hearts as depicted in 
Figure 3Q (p < 0.05).
Reduced Infarct Region Following TIMP-1- 
ES Cell Transplantation
Representative whole-heart images depicting infarct 
size are represented in Figure 4A. Following quantifica-
tion of infarct size, we reveal that the dramatic increase 
in infarct dimensions observed within the control MI + CC 
group was significantly blunted following transplanta-
tion of ES and TIMP-1-ES cells ( p < 0.001) (Fig. 4B). 
Furthermore, our data demonstrate the extent of infarcted 
region within TIMP-1-ES cell transplanted hearts was 
significantly decreased compared to ES cell-transplanted 
hearts suggesting TIMP-1-ES cells are superior in reducing 
infarct size compared with ES cells ( p < 0.01) (Fig. 4B).
Transplanted TIMP-1-ES Cells Prevent Apoptosis  
in the Infarcted Heart
To determine whether transplanted ES cells over-
expressing TIMP-1 inhibit apoptosis compared to ES cells 
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in the host myocardium, TUNEL staining was performed 
(Fig. 5). At D14, there was a significant decrease in 
TUNEL-positive nuclei post-MI in the infarct and peri- 
infarct regions of hearts transplanted with ES cells 
compared to controls ( p < 0.001) (Fig. 5Q). Moreover, 
 TIMP-1-ES cell-transplanted hearts contained signifi-
cantly fewer total apoptotic nuclei compared to ES cell 
and cell culture medium groups (mean ± SEM; MI + TIMP-
1-ES cells: 0.63 ± 0.06% vs. MI + ES cells: 0.94 ± 0.07% 
and MI + CC: 1.55 ± 0.12%, TUNEL positive/total nuclei, 
p < 0.05) (Fig. 5Q). Additionally, heart sections were cola-
beled with sarcomeric a-actin to demonstrate and quanti-
tate apoptosis within cardiac myocyte nuclei (Fig. 5M–P). 
Our data show apoptotic cardiac myocyte nuclei were sig-
nificantly reduced in hearts transplanted with TIMP-1-ES 
cells compared with ES cell and media-transplanted hearts 
( p < 0.05) (Fig. 5R). Next, to strengthen our TUNEL data, 
a caspase-3 colorimetric assay was performed on heart 
homogenates from each group. There was a significant 
decrease in caspase-3 activity in hearts treated with TIMP-
1-ES cells post-MI compared to hearts transplanted with 
ES cells or medium alone (mean ± SE; MI + TIMP-1-ES 
cells: 171.75 ± 2.56 vs. MI + ES cells: 188.50 ± 1.80 and 
MI + CC: 203.00 ± 4.36, p < 0.05) (Fig. 6A).
TIMP-1 Enhances p-Akt Activation in Post-MI Hearts
Previous studies have shown that mechanisms of inhib-
ited apoptosis involve the activation of cell survival path-
ways including p-Akt (38). Our data demonstrate that hearts 
transplanted with TIMP-1-ES cells did in fact have sig-
nificant increase in the activation of p-Akt compared to 
hearts transplanted with ES cells and medium (mean ± SE; 
Figure 1. TIMP-1 vector and the generation of TIMP-1-ES cells. (A) Tissue inhibitor of metalloproteinases-1 (TIMP-1) cDNA was 
cloned into the pTurboFP635-C expression vector encoding red fluorescent protein (RFP). TIMP-1-ES (TIMP-1-embryonic stem) 
cells were selected following incubation with the selective antibiotic G418. Representative photomicrographs of TIMP-1-ES cells 
in bright field microscopy (B) and under fluorescence microscopy (C) to demonstrate RFP expression. (D) Representative photomi-
crographs of Western blot. Histogram shows significant overexpression of TIMP-1 in TIMP-1-ES cells relative to parental ES cells. 
*p < 0.001 versus ES cells. (E) Histogram shows quantitative analysis of secreted TIMP-1 in ES and TIMP-1-ES cells. *p < 0.05 versus 
ES cells. MCS, multiple cloning site.
1936 GLASS AND SINGLA
MI + TIMP-1-ES cells: 6.99 ± 0.22 vs. MI + ES cells: 
5.75 ± 0.16 and MI + CC 4.61 ± 0.25, p < 0.05) (Fig. 6B), 
suggesting upregulation of cell survival pathways. 
Reduced Fibrosis Following MI in TIMP-1-ES Cell 
Group (Fig. 7)
Interstitial fibrosis in the infarcted heart sections was 
measured at D14 and representative photomicrographs 
from each group are depicted in Figure 7A–D. Compared 
to medium alone, ES cell-transplanted hearts had a signifi-
cant reduction in the amount of total interstitial fibrosis 
( p < 0.01) (Fig. 7I). Furthermore, the reduced interstitial 
fibrosis observed in TIMP-1-ES cell-transplanted hearts 
was significant when compared to ES cell and control 
hearts (mean ± SE; MI + TIMP-1-ES cell: 0.23 ± 0.03 mm2 
vs. MI + ES cells: 0.47 ± 0.02 mm2 and MI + CC: 0.90 ± 
0.00 mm2, p < 0.01) (Fig. 7I). 
Next, quantitative assessment of vascular fibrosis 
(Fig. 7E–H) revealed ES cell-transplanted hearts had a sig-
nificant decrease in the amount of vascular fibrosis com-
pared to medium alone ( p < 0.001) (Fig. 7J). Furthermore, 
the attenuation of vascular fibrosis in TIMP-1-ES cell-
transplanted hearts reached statistical significance when 
compared to ES cells ( p < 0.05) (Fig. 7J).
To determine whether inhibition of fibrosis was 
associated with changes in MMP-9, a well-documented 
MMP involved in the pathogenesis of MI, MMP-9 was 
quantified using an enzyme-linked immunoassay. Hearts 
transplanted with ES cells demonstrated significantly 
reduced MMP-9 concentration compared with control 
Figure 2. Enhanced engraftment of TIMP-1-ES cells in the infarcted myocardium. Representative photomicrographs showing heart 
sections stained with anti-octamer binding transcription protein 3/4 (Oct 3/4) for pluripotent cells in red (A and E), donor trans-
planted cells in green (B and F), nuclei stained with DAPI in blue (C and G), and the merged image (D and H). Scale bar: 20 mm. 
(I) Quantitative analysis of engrafted cells at D1 following myocardial infarction (MI). (J) Significant increase in engrafted TIMP-
1-ES cells at D14. *p < 0.05 versus MI + ES cells. CC, cell culture media.
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Figure 3. TIMP-1 enhances differentiation of ES cells into cardiac myocytes. Representative photomicrographs showing heart sec-
tions stained with anti-a-actin for cardiac myocytes in red (A, E, I, and M), anti-RFP for donor transplanted cells in green (B, F, J, 
and N), nuclei stained with DAPI in blue (C, G, K, and O), and the merged image (D, H, L, and P) showing coexpression of a-actin 
and RFP indicating differentiated donor cells. Scale bar: 20 mm. (Q) Quantitative analysis of differentiated donor ES cells into cardiac 
myocytes 2 weeks following MI. *p < 0.05 versus ES cells.
Figure 4. TIMP-1 reduces infarct size following MI. (A) Representative photomicrographs of hearts 
demonstrating infarct size from C57BL/6 mice 2 weeks post-MI or sham surgery. Scale bar: 500 mm. 
(B) Histogram shows infarct size was significantly reducing following transplantation of TIMP-
1-ES cells. *p < 0.001 versus MI + CC and #p < 0.001 versus MI + CC and MI + ES cells. LV = left 
ventricle.
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hearts ( p < 0.01) (Fig. 7K). Moreover, MMP-9 concentra-
tion within TIMP-1-ES cell-transplanted hearts was signif-
icantly less compared to hearts transplanted with ES cells 
or media (mean ± SE; MI + TIMP-1-ES cells: 21.19 ± 1.27 
vs. MI + ES cells: 41.64 ± 3.83 and MI + CC: 63.81 ± 8.18, 
p < 0.01) (Fig. 7K).
Overexpression of TIMP-1 Improves Cardiac Function 
Post-MI
To evaluate the cardiac functional consequences of 
transplanted TIMP-1-ES cells post-MI, two-dimensional 
echocardiography was performed. Obtained primary raw 
data are depicted in Figure 8A. Cumulative quantitative 
data revealed that, although a trend of decreased LVIDd 
was observed between TIMP-1-ES cell-transplanted 
mice and ES cell or CC-transplanted mice, statistical 
significance was not attained (Fig. 8B). Conversely, left 
ventricular dimensions during systole were significantly 
reduced following transplantation of TIMP-1-ES cells 
relative to mice transplanted with ES cells or CC ( p < 
0.05) (Fig. 8C). Cardiac function data at D14 further sug-
gest mice receiving ES cell transplantation following MI 
had significantly improved fractional shortening com-
pared to medium alone ( p < 0.001) (Fig. 8D). Moreover, 
mice transplanted with TIMP-1-ES cells post-MI had sig-
nificantly increased fractional shortening when compared 
Figure 5. Effects of transplanted ES cells overexpressing TIMP-1 on host cardiac myocyte apoptosis in C57BL/6 mice. ES and TIMP-
1-ES cells were transplanted post-MI and hearts were examined for apoptosis 2 weeks following cell transplantation. Representative 
photomicrographs of total nuclei stained with DAPI in blue (A–D), apoptotic nuclei stained with Terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling (TUNEL) in red (E–H), and merged nuclei in pink (I–L). Scale bar: 100 mm. (M–P) Set of represen-
tative photomicrographs of section labeled with sarcomeric a-actin (M), apoptotic nuclei stained with TUNEL in red (N), total 
nuclei stained with DAPI in blue (O), and merged image (P) demonstrating apoptosis occurs within the cardiac myocyte. Scale bar: 
50 mm. Boxed area in (O) enlarged to show colocalization of sacromeric a-actin, TUNEL-positive nucleus, and DAPI. (Q) Total 
apoptotic nuclei in the infarct and peri-infarct regions of the heart in one to two sections from five to eight hearts from each group. 
*p < 0.001 versus MI + CC, #p <0.05 versus MI + CC and MI + ES cells. (R) Quantitative cardiac myocyte apoptotic data. *p < 0.01 ver-
sus MI + CC, #p < 0.05 versus MI + CC and MI + ES cells. 
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to mice transplanted with ES cells and medium post-MI 
at D14 (mean ± SE; MI + TIMP-1-ES cells: 44.81 ± 0.70% 
versus MI + ES cells: 41.01 ± 0.61% and MI + CC: 31.30 ± 
0.88%, p < 0.05) (Fig. 8D). 
End diastolic and systolic volumes are depicted in 
Figure 8E and F, respectively, for all study groups. As 
a dramatic reduction in ejection fraction was observed 
in MI + CC mice, this decrease was significantly blunted 
in mice transplanted with TIMP-1-ES and ES cells ( p < 
0.001) (Fig. 8G). Notably, mice transplanted with TIMP-
1-ES cells additionally had significantly enhanced ejec-
tion fraction when compared with ES cell-transplanted 
mice ( p < 0.05) (Fig. 8G). 
DISCUSSION
Many stem cell types examined thus far including skel-
etal myoblasts, bone marrow stem cells, bone marrow- 
derived hematopoietic stem cells, endogenous cardiac 
stem cells, mesenchymal stem cells, induced pluripo-
tent stem (iPS) cells, and ES cells have shown improved 
cardiac function following transplantation post-MI 
(16,26,27,30,33). Improvement in cardiac function in 
past studies was demonstrated by newly differentiated 
cardiac myocytes and inhibition of apoptosis and fibro-
sis. However, observed effects of stem cell transplanta-
tion following MI was not enough to provide complete 
protection required to reestablish normal heart func-
tion. Therefore new strategies, such as modulation of 
ES cells using antiapoptotic and antifibrotic genes, are 
required. In the present study, we transfected ES cells 
with TIMP-1, an antiapoptotic and antifibrotic gene, 
transplanted them into the myocardium post-MI, and 
evaluated their effects on cardiac myocyte engraftment 
and differentiation, myocardial remodeling (apoptosis 
and fibrosis), and cardiac function.
Well-documented, endogenous TIMP-1 has been 
shown to be found within the extracellular matrix, 
membrane bound at the cell surface, and localized to 
the nucleus (22,31). The discriminating benefit propa-
gated by constitutively active vector-driven TIMP-1 
expression in ES cells is that TIMP-1 has the poten-
tial to exert its effects in an autocrine-mediated man-
ner protecting transplanted ES cells from cell death or 
through paracrine mechanisms protecting the injured 
myocardium. We show that following transfection with 
the TIMP-1-RFP construct, the fusion proteins are 
abundantly expressed in and secreted by TIMP-1-ES 
cells. Previous studies have shown similar results indi-
cating generated TIMP-1-GFP or TIMP-1-RFP fusion 
constructs are processed analogous to endogenous 
TIMP-1 (11,31). 
The feasibility of exogenous transplanted cells to 
engraft into the infarcted myocardium is well documented 
(4,16,29,33). ES cells, derived from the inner cell mass 
of the blastocyst, are advantageous for nonautologous 
cell transplantation in that they confer minimal immuno-
reactivity consequent to the limited number to major 
histocompatibility complex surface proteins. Our study 
provides evidences indicating the enhanced survival of 
TIMP-1-ES cells in the injured myocardium follow-
ing transplantation. Notably, these data for the first time 
suggest that a significant increase in TIMP-1-ES cells 
remain engrafted in the myocardium 2 weeks following 
transplantation contrary to the common observation that 
the majority of transplanted cells die within the first few 
days (5,32,48).
Figure 6. Effects of TIMP-1-ES cell transplantation on caspase-3 and p-Akt expression. (A) Quantitative analysis of caspase-3 
activity in hearts transplanted with and without stem cells. *p < 0.05 versus MI + CC, #p < 0.05 versus MI + CC and MI + ES cells. 
(B) Quantitative analysis of phospho-Akt activation. *p < 0.01 versus MI + CC, #p < 0.01 versus MI + CC and MI + ES cells.
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Regeneration of the infarcted heart is imperative to 
restoring the heart to pre-MI homeostasis. Intensive in 
vitro and in vivo research is underway using various fac-
tors to enhance and promote cardiac myocyte differen-
tiation from stem cell populations (10,39,46,47). In this 
study, we have shown that our RFP-positive donor cells 
were elongated, nucleated, striated, and positive for sarco-
meric a-actin. These characteristics of our RFP-positive 
cells indicate that not only do the transplanted cells sur-
vive in the injured myocardium but also differentiate into 
mature cardiac myocytes. Moreover, we have shown for 
the first time enhanced cardiac myocyte differentiation 
from transplanted ES cells post-MI by overexpression 
of TIMP-1. Our results are consistent with recent find-
ings demonstrating the ability of TIMP-1 to promote 
oligodendrocyte, germinal center B cell, and UT-7 eryth-
roid cell differentiation (8,17,28). 
Next, we wanted to understand the effects of trans-
planted TIMP-1-ES cells on endogenous cardiac apop-
tosis. Well established, apoptosis is a major mechanism 
by which cardiac myocyte cell death occurs following 
MI leading to hypertrophy, fibrosis, and ultimately poor 
cardiac function. TIMP-1 has recently been identified as 
antiapoptotic in various cell lines including human osteo-
sarcoma cells (MG-63), mouse bone marrow stromal 
cells (MBA-1), murine MC3T3-E1 osteoblasts, human 
breast epithelial cells, and rat cardiomyoblasts (H9c2) 
(24,35,43,44). The present study demonstrates a signifi-
cant reduction in apoptosis in the host myocardium fol-
lowing transplantation with TIMP-1-ES cells compared 
Figure 7. Effects of transplanted ES cells overexpressing TIMP-1 on interstitial and vascular fibrosis. Representative photomicro-
graphs from sections stained with Masson’s trichrome 2 weeks following coronary artery ligation demonstrating interstitial (A–D) and 
vascular (E–H) fibrosis. Scale bar: 100 mm. (I) Quantitative total interstitial fibrosis per section. *p < 0.01 versus MI + CC, #p < 0.05 
versus MI + CC and MI + ES cells. (J) Quantitative analysis of vascular fibrosis in heart sections. *p < 0.001 versus MI + CC, #p < 0.01 
versus MI + CC and MI + ES cells. VA, vessel area; VF, vessel fibrosis. (K) Average matrix metalloproteinase-9 (MMP-9) concentra-
tion within hearts from each group. *p < 0.01 versus MI + CC, #p < 0.05 versus MI + CC and MI + ES cells. 
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to ES cells confirmed by TUNEL staining and caspase-3 
activity assay. Our data are in accordance with a previ-
ously published study suggesting TIMP-1 conditioned 
media (CM) prevents H2O2-induced apoptosis in an in 
vitro model similar to ischemic myocardium (35). 
Previous studies have reported a positive correlation 
between TIMP-1 and activation of the Akt signaling 
cascade-promoting breast epithelial and UT-7 erythroid 
cell survival (1,21). Our present study also provides evi-
dence indicating hearts transplanted with TIMP-1-ES 
cells had significant activation of p-Akt compared to 
hearts transplanted with ES cells and medium controls. 
Although future detailed studies are necessitated to deter-
mine the exact mechanisms of the TIMP-1 antiapoptotic 
influence, our findings are in corroboration with previ-
ous studies suggesting mechanisms of inhibited apoptosis 
involve the activation of cell survival pathways including 
Akt (38). 
Fibrosis, a major contributor to adverse cardiac 
remodeling, is consequent to increased MMP activation 
post-MI, which leads to ECM degradation, increased col-
lagen deposition, stiffening of the heart, and ultimately 
Figure 8. TIMP-1 overexpressed in ES cells improves cardiac function in C57BL/6 mice. Echocardiography was performed D14 
following MI and fractional shortening and ejection fraction were quantified. (A) Primary raw data obtained from echocardiography 
analysis. (B) Average Left ventricular internal dimension-diastole (LVIDd). (C) Average LVIDs (systole). *p < 0.01 versus MI + CC 
and #p < 0.05 versus MI + CC and MI + ES cells. (D) Average fractional shortening at 2 weeks post-MI for all treatment groups. 
*p < 0.001 versus MI + CC, #p < 0.05 versus MI + CC and MI + ES cells. (E) Average EDV (left ventricular volume at end diastole). 
*p < 0.05 versus MI + CC. (F) Average ESV (left ventricular volume at end systole). *p < 0.001 versus MI + CC and #p < 0.05 versus 
MI + CC and MI + ES cells. (G) Quantified average ejection fraction. *p < 0.001 versus MI + CC, #p < 0.05 versus MI + CC and MI + ES 
cells. Data set is from n = 8 different animals/group. 
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poor cardiac function. In the present study, our cardiac 
fibrosis data (interstitial and vascular fibrosis) demon-
strate significantly reduced fibrosis in hearts treated with 
TIMP-1-ES cells compared with hearts transplanted with 
ES cells. Additionally, hearts transplanted with TIMP-
1-ES cells contained significantly less MMP-9 compared 
with ES cell and CC groups post-MI. These data are 
supported by previous studies indicating a reduction in 
MMP-9 expression in the presence of TIMP-1 overexpres-
sion (42). Following an MI, increased MMP activation is 
not paralleled by an increase in TIMP-1 expression (45). 
Therefore, we suggest significant reduction in the post-MI 
fibrosis observed in the TIMP-1-ES cell- transplanted 
hearts compared to ES cell-transplanted hearts may be 
attributable to inhibition of MMP-9 through overexpres-
sion of TIMP-1. However, further studies are required to 
define these mechanisms. 
Finally, we needed to determine whether an increase 
in newly differentiated cardiac myocytes and inhibi-
tion of apoptosis and fibrosis in the host myocardium 
contribute to a decrease in infarct size and ultimately 
improve cardiac function following MI in TIMP-1-ES 
cell-transplanted animals. Infarcted myocardium con-
tributes to aberrant left ventricular stiffness and diastolic 
dysfunction post-MI. Within the current study, we have 
shown a large infarct scar post-MI in the MI + CC control 
group. However, the infarct scar region was significantly 
diminished following TIMP-1-ES cell transplantation. 
Conceivably, we suggest that increased engraftment and 
differentiation following TIMP-1-ES cell transplanta-
tion repopulated the heart with additional functional 
cardiac myocytes, thereby reducing the infarct scar size. 
Moreover, in the present study, our data demonstrate that 
2 weeks following MI, mice transplanted with TIMP-
1-ES cells had significantly increased fractional shorten-
ing and ejection fraction compared to mice transplanted 
with ES cells or cell culture medium. We recognize that 
the mechanisms of improved cardiac function are com-
plex and multifactorial. We do however suggest that the 
decrease in apoptosis and fibrosis, which is correlated 
with a decrease in infarct scar size, is directly related to 
the modulation of cardiac function observed within the 
current study. It is possible also to assert that improve-
ment in ventricular function may be consequent to bene-
ficial autocrine and paracrine mechanisms of TIMP-1 
leading to continual differentiation of cardiac myocytes 
from transplanted TIMP-1-ES cells and protection of 
the host myocardium respectively leading to a decreased 
infarct size and ultimately cardiogenesis. These results 
are consistent with recent findings demonstrating regen-
eration of the infarcted myocardium following transplan-
tation of ES cells (20,32,34). Findings from this study 
indicate that transplantation of TIMP-1-ES cells attenuate 
adverse cardiac remodeling and improve heart function 
following MI. 
In conclusion, the major findings of the present study 
involving TIMP-1-overexpressing ES cells relative to ES 
cells include the following for the first time: (1) engraft-
ment and differentiation into cardiac myocytes are sig-
nificantly upregulated in transplanted TIMP-1-ES cells, 
(2) infarct size is significantly diminished in TIMP-1-ES 
cell-transplanted hearts, (3) TIMP-1-ES cells significant ly 
inhibit cardiac apoptosis in the infarcted myocardium, 
(4) inhibition of apoptosis in hearts transplanted with 
TIMP-1-ES cells is mediated, in part, through the Akt 
pathway, (5) transplanted TIMP-1-ES cells significantly 
inhibit interstitial and vascular fibrosis as well as the 
profibrotic protein, MMP-9, following MI, and (6) trans-
planted TIMP-1-ES cells significantly improve overall 
cardiac function following MI through retention of func-
tional cardiac myocytes and maintenance of the integ-
rity of the host myocardium. However, future studies are 
required to identify further detailed mechanisms by which 
TIMP-1 prevents apoptosis and fibrosis in the infarcted 
myocardium. Additionally, as TIMP-1 is a secreted fac-
tor from ES cells, future studies are warranted to assess 
the role of TIMP-1-ES-CM in the infarcted myocar-
dium, as previous studies have shown cytoprotective 
effects of CM in in vitro and in vivo models of ischemic 
myocardium (36,37).
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